Uptake of Antifibrotics for Patients with Idiopathic Pulmonary Fibrosis: 2016-2022
Ann Am Thorac Soc
.
2024 Jan;21(1):170-173.
doi: 10.1513/AnnalsATS.202308-697RL.
Authors
Divya A Shankar
1
,
Finn Hawkins
1
,
Konstantinos-Dionysios Alysandratos
1
,
Kevin C Wilson
1
,
Allan J Walkey
1
,
Nicholas A Bosch
1
,
Anica C Law
1
Affiliation
1
Boston University School of Medicine Boston, Massachusetts.
PMID:
37879035
PMCID:
PMC10867915
DOI:
10.1513/AnnalsATS.202308-697RL
No abstract available
Publication types
Letter
MeSH terms
Humans
Idiopathic Pulmonary Fibrosis* / drug therapy
Pyridones / therapeutic use
Substances
Pyridones
Grants and funding
KL2 TR001411/TR/NCATS NIH HHS/United States
R01 HL136660/HL/NHLBI NIH HHS/United States
R01 HL139799/HL/NHLBI NIH HHS/United States
R01 HL139751/HL/NHLBI NIH HHS/United States
F32 HL168959/HL/NHLBI NIH HHS/United States
R01 HL151607/HL/NHLBI NIH HHS/United States
OT2 HL156812/HL/NHLBI NIH HHS/United States
UL1 TR001430/TR/NCATS NIH HHS/United States
K08 HL163494/HL/NHLBI NIH HHS/United States
1F32HL168959-01/HL/NHLBI NIH HHS/United States
K23 HL153482/HL/NHLBI NIH HHS/United States
T32 HL007035/HL/NHLBI NIH HHS/United States